This is reinforced by a prospective trial, which enrolled 981 patients and highlighted that low serum levels of IL-17 were linked with a higher risk of all-cause death and recurrent myocardial infarction in Caucasian patients after 2-year follow-up (55). This evidence concerns the gene IL17A and myocardial infarction.